Express Scripts is suing the Federal Trade Commission (FTC), demanding the retraction of a report it claims is false and harmful to the pharmacy benefit manager (PBM) industry.

There's little point in pouring hundreds of millions of dollars into creating a biosimilar if PBMs will refuse to cover it.

What they found: The PBMs marked up prices for specialty generic drugs by hundreds and sometimes thousands of percent over their estimated acquisition costs from 2017 and 2022, per the FTC report.

Opinion: Miami attorney Gregg Goldfarb says wielding antitrust, fraud, and nuisance claims can help attorneys score wins in ...

The FTC released a 60-page report Tuesday targeting the biggest three pharmacy benefit managers, claiming the companies hiked the prices of specialty drugs to generate $7.3 billion in revenue from ...

FTC investigators documented how pharmacy benefit managers imposed eye-popping markups on generic drugs used to treat deadly ...

The FTC’s First Interim Report found that pharmacies affiliated with the three largest PBMs in the United States received 68 percent of all revenue for dispensing specialty drugs in 2023 (up ...

Pharmacy benefit managers (PBMs) are coming under increased public scrutiny for their role in the healthcare industry. Last month the FTC released an interim report on their two-year investigation ...

In its administrative complaint, the FTC alleges that these practices violate the FTC Act, artificially inflate prices and make it more difficult for patients to access insulin.

Express Scripts parent company Cigna alleges the Federal Trade Commission ignored more than 3 million pages of documents the pharmacy provided to investigators.

Cigna's Express Scripts sues FTC over 'defamatory' PBM report The FTC says it has clear authority to help policymakers understand how PBMs work.

FTC's July 2024 report makes unsubstantiated, false and biased claims about the PBM industry; fails to take into account the value that PBMs deliver to consumers and patients Information about ...